2023
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters (Journal article)
Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. VIRUSES-BASEL, 15(8). doi:10.3390/v15081744DOI: 10.3390/v15081744
Neary, M., Arshad, U., Tatham, L., Pertinez, H., Box, H., Rajoli, R. K. R., . . . Owen, A. (2023). Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1228. doi:10.1016/j.jchromb.2023.123823DOI: 10.1016/j.jchromb.2023.123823
Curley, P., Hobson, J. J., Liptrott, N. J., Makarov, E., Al-Khouja, A., Tatham, L., . . . Owen, A. (2023). Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.. Pharmaceutics, 15(7), 1835. doi:10.3390/pharmaceutics15071835DOI: 10.3390/pharmaceutics15071835
Gaynor, K. U. U., Vaysburd, M., Harman, M. A. J., Albecka, A., Jeffrey, P., Beswick, P., . . . James, L. C. C. (2023). Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-39158-1DOI: 10.1038/s41467-023-39158-1
BUZIBYE, A. L. L. A. N., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.. AIDS Research and Therapy. doi:10.1186/s12981-023-00514-2DOI: 10.1186/s12981-023-00514-2
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. (Preprint)
DOI: 10.1101/2022.01.23.477397
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., . . . Sampaziotis, F. (2023). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. NATURE, 615(7950), 134-+. doi:10.1038/s41586-022-05594-0DOI: 10.1038/s41586-022-05594-0
Buzibye, A., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study.. AIDS research and therapy, 20(1), 20. doi:10.1186/s12981-023-00514-2DOI: 10.1186/s12981-023-00514-2
2022
Neary, M., Owen, A., & Olagunju, A. (2022). A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm. Clinical Infectious Diseases, 75(Supplement_4), S490-S497. doi:10.1093/cid/ciac685DOI: 10.1093/cid/ciac685
Neary, M. (2022). An assessment of the preclinical development of long-acting biodegradable emtricitabine implants. In International Workshop of Clinical Pharmacology. Barcelona, Spain.
Shakil, A., Hern, F. Y., Liu, C., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2022). Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. JOURNAL OF MATERIALS CHEMISTRY B, 10(23), 4395-4404. doi:10.1039/d2tb00825dDOI: 10.1039/d2tb00825d
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays. (Preprint)
DOI: 10.1101/2022.03.03.482788
2021
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309gDOI: 10.1039/d1nr00309g
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619DOI: 10.1111/bcp.14619
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035.v1DOI: 10.26434/chemrxiv.13587035.v1
In vitro/ in vivo development of long acting biodegradable emtricitabine implants (Conference Paper)
Neary, M., Sharp, J., Curley, P., Pertinez, H., Box, H., Tatham, L., . . . Owen, A. (2021, March 6). In vitro/ in vivo development of long acting biodegradable emtricitabine implants. In Conference on Retroviruses and Opportunistic Infections. Online.
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Neary, M., . . . Owen, A. (2021). Optimisation and validation of a sensitive bioanalytical method for niclosamide. doi:10.1101/2021.01.13.426426DOI: 10.1101/2021.01.13.426426
2020
Pharmacokinetics of HIV therapies in pregnant patients: an update (Journal article)
Neary, M., Owen, A., & Olagunju, A. (2020). Pharmacokinetics of HIV therapies in pregnant patients: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 16(6), 449-461. doi:10.1080/17425255.2020.1754792DOI: 10.1080/17425255.2020.1754792
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130DOI: 10.1101/2020.05.01.20087130
Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population (Journal article)
Neary, M., Olagunju, A., Sarfo, F., Phillips, R., Moss, D., Owen, A., & Chadwick, D. (2020). Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1267-1271. doi:10.1093/jac/dkaa008DOI: 10.1093/jac/dkaa008
Elliot, E. R., Neary, M., Else, L., Khoo, S., Moyle, G., Carr, D. F., . . . Owen, A. (2020). Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1259-1266. doi:10.1093/jac/dkz558DOI: 10.1093/jac/dkz558
2019
Ayuso, P., Neary, M., Chiong, J., & Owen, A. (2019). Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(11), 3281-3290. doi:10.1093/jac/dkz329DOI: 10.1093/jac/dkz329
Neary, M., Chappell, C. A., Scarsi, K. K., Nakalema, S., Matovu, J., Achilles, S. L., . . . Lamorde, M. (2019). Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(10), 3003-3010. doi:10.1093/jac/dkz298DOI: 10.1093/jac/dkz298
The Preclinical Evaluation of an Atazanavir Solid Drug Nanoparticle Formulation (Conference Paper)
Box, H., Sharp, J., Neary, M. G., Tatham, L., Savage, A., Rannard, S., & Owen, A. (2019). The Preclinical Evaluation of an Atazanavir Solid Drug Nanoparticle Formulation. In Early Career Researcher Meeting British Society of Nanomedicine. Glasgow.
Initial assessment of the suitability of Galleria mellonella for the study of long acting formulations. (Conference Paper)
Neary, M., Sharp, J., Curley, P., Whiteford, S., Liptrott, N., & Owen, A. (2019). Initial assessment of the suitability of Galleria mellonella for the study of long acting formulations.. In Early Career Researcher Meeting British Society of Nanomedicine. Glasgow.
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide (Journal article)
Cerrone, M., Alfarisi, O., Neary, M., Marzinke, M. A., Parsons, T. L., Owen, A., . . . Boffito, M. (2019). Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1670-1678. doi:10.1093/jac/dkz068DOI: 10.1093/jac/dkz068
Effect of CYP2B6 Metabolizer Status on Levonorgestrel Pharmacokinetics When Combined with Efavirenz-based Antiretroviral Therapy (Conference Paper)
Pham, M., Mbabzi, O., Neary, M. G., Nakalema, S., Campbell, K., Cirrincione, L., . . . Kimberly, S. (2019). Effect of CYP2B6 Metabolizer Status on Levonorgestrel Pharmacokinetics When Combined with Efavirenz-based Antiretroviral Therapy. In PK workshop. Amsterdam, Netherlands.
Effect of tenofovir and abacavir on dolutegravir transport in vitro and in vivo (Conference Paper)
Neary, M. G., Tatham, L., Sharp, J., Ayuso, P., Abutaima, R., Box, H., . . . Owen, A. (2019, May 14). Effect of tenofovir and abacavir on dolutegravir transport in vitro and in vivo. In 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs.. Hotel Oranje, Noordwijk, NL.
Impact of CYP2B6 genotype on prevalence of EFV resistance in mothers who are retained or disengaged from Option B+. (Conference Paper)
Buzibye, A., Olagunju, A., Twinomuhwezi, E., Kara, W. -K., Owen, A., Waitt, C., . . . Neary, M. G. (n.d.). Impact of CYP2B6 genotype on prevalence of EFV resistance in mothers who are retained or disengaged from Option B+.. In the 13th International Conference on the HIV Treatment, Pathogenesis, and Prevention Research in Resource-Limited Settings (INTEREST). Accra Ghana.
Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111DOI: 10.2217/pgs-2018-0111
Kaboggoza, J. P., Wang, X., Neary, M., Ayuso, P., Sekaggya-Wiltshire, C., Nakalema, S., . . . Boffito, M. (2019). A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. OPEN FORUM INFECTIOUS DISEASES, 6(2). doi:10.1093/ofid/ofz035DOI: 10.1093/ofid/ofz035
Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals (Journal article)
Cerrone, M., Wang, X., Neary, M., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (2019). Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. CLINICAL INFECTIOUS DISEASES, 68(3), 446-452. doi:10.1093/cid/ciy491DOI: 10.1093/cid/ciy491
2018
Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir (Conference Paper)
Savage, A., Ashcroft, S., Box, H., Sharp, J., Neary, M., Owen, A., & Rannard, S. (2018). Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum (Journal article)
Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika-Kibwika, P., . . . Boffito, M. (2018). Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. CLINICAL INFECTIOUS DISEASES, 67(5), 785-790. doi:10.1093/cid/ciy161DOI: 10.1093/cid/ciy161
Improved Oral In Vivo Pharmacokinetics of Novel Oil in Water Solid Drug Nanoparticle formulations of Tenofovir Disoproxil Fumarate for the treatment of HIV (Conference Paper)
Curley, P., Hobson, J., David, C., Box, H., Neary, M. G., Sharp, J., . . . Owen, A. (n.d.). Improved Oral In Vivo Pharmacokinetics of Novel Oil in Water Solid Drug Nanoparticle formulations of Tenofovir Disoproxil Fumarate for the treatment of HIV. In CLINAM European Foundation for Clinical Nanomedicine.
Neary, M. G. (2018, May 8). Assessment of the inter-individual variation observed between patients receiving HIV antiretroviral therapy.
Elliot, E., Neary, M. G., Else, L., Khoo, S., Moyle, G., Carr, D., . . . Boffito, M. (n.d.). ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.. In CROI. Boston, MA, USA.
Neary, M. G., Chappell, C., Scarsi, K., Nakalema, S., Matovu, J., Achilles, S., . . . Lamorde, M. (2018, March 5). CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.. In CROI. Boston, MA, USA.
Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV. (Conference Paper)
Cerrone, M., Xinhu, W., Neary, M. G., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (n.d.). Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV.. In CROI. Boston, MA, USA.
Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation. (Conference Paper)
Box, H., Sharp, J., Neary, M. G., Moss, D., Tatham, L., Savage, A., . . . Owen, A. (n.d.). Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.. In CROI. Boston, MA, USA.
Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics. (Conference Paper)
Cerrone, M., Alfarisi, O., Neary, M. G., Marzinke, O., Parsons, T., Owen, A., . . . Boffito, M. (n.d.). Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics.. In CROI. Boston, MA, USA.
2017
Pharmacogenetic considerations for HIV treatment in different ethnicities: an update (Journal article)
Neary, M., & Owen, A. (2017). Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 13(11), 1169-1181. doi:10.1080/17425255.2017.1391214DOI: 10.1080/17425255.2017.1391214
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667DOI: 10.1002/cpt.667
ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine. (Conference Paper)
Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (n.d.). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.
Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum (Conference Paper)
Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika, P., . . . Boffito, M. (2017). Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 122). Retrieved from https://www.webofscience.com/
2016
Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study (Journal article)
Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227DOI: 10.1097/FPC.0000000000000227
Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy. (Conference Paper)
Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (n.d.). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.
2014
The role of drug transporters in the kidney: lessons from tenofovir (Journal article)
Moss, D. M., Neary, M., & Owen, A. (2014). The role of drug transporters in the kidney: lessons from tenofovir. FRONTIERS IN PHARMACOLOGY, 5. doi:10.3389/fphar.2014.00248DOI: 10.3389/fphar.2014.00248
